Neisvac-C está indicado para la inmunización activa en niños desde los 2 meses de edad, adolescentes y adultos, para la prevención de enfermedades invasivas causadas por Neisseria meningitidis de serogrupo C. El uso de NeisVac-C se determinará en función de las recomendaciones oficiales. 4.2 Posología y forma de administración
NeisVac-C. Adsorbierter Meningokokken- Serogruppe C- Polysaccharid- Konjugatimpfstoff. Verwendung ab einem Lebensalter von 2 Monaten / Use from an age of 2 months. Orifarm GmbH. Mono: PEI.H.11796.01.1: 14.12.2015: PharmNet.Bund. Parallelimport. NeisVac-C. Adsorbierter Meningokokken- Serogruppe C- Polysaccharid- Konjugatimpfstoff
given NeisVac-C against the benefits it is expected to provide. If you have any concerns about taking this vaccination, ask your doctor or pharmacist. Keep this leaflet. You may need to read it again. What NeisVac-C is used for NeisVac-C is a vaccine, a type of medicine used to protect against infectious diseases. NeisVac-C is
NEISVAC-C susp inj: Méningocoques C, vaccin conjugué; seringue préremplie 0.5 ml: Liste B, LS: quote-part normale: 10% (LIM), CHF 45.25
FICHA TECNICA NEISVAC-C 0,5 ml SUSPENSIÓN INYECTABLE EN JERINGA PRECARGADA. NeisVac-C se administrará en inyección intramuscular, preferiblemente en la región anterolateral del muslo en niños menores de 12 meses, y en la región deltoidea en niños mayores, adolescentes y adultos.
NeisVac-C. Adsorbierter Meningokokken- Serogruppe C- Polysaccharid- Konjugatimpfstoff. Verwendung ab einem Lebensalter von 2 Monaten / Use from an age of 2 months. Orifarm GmbH. Mono: PEI.H.11796.01.1: 14.12.2015: PharmNet.Bund.
Parallelimport. NeisVac-C. Adsorbierter Meningokokken- Serogruppe C- Polysaccharid- Konjugatimpfstoff given NeisVac-C against the benefits it is expected to provide. If you have any concerns about taking this vaccination, ask your doctor or pharmacist. Keep this leaflet.
You may need to read it again. What NeisVac-C is used for NeisVac-C is a vaccine, a type of medicine used to protect against infectious diseases. NeisVac-C is NEISVAC-C susp inj: Méningocoques C, vaccin conjugué; seringue préremplie 0.5 ml: Liste B, LS: quote-part normale: 10% (LIM), CHF 45.25 FICHA TECNICA NEISVAC-C 0,5 ml SUSPENSIÓN INYECTABLE EN JERINGA PRECARGADA. NeisVac-C se administrará en inyección intramuscular, preferiblemente en la región anterolateral del muslo en niños menores de 12 meses, y en la región deltoidea en niños mayores, adolescentes y adultos.
NeisVac-C® (meningococcal group C-TT conjugate vaccine, adsorbed) Product Monograph Page 5 of 23 It would be anticipated that functionally or anatomically asplenic individuals would mount an immune response to meningococcal C conjugate vaccines; however, there are
NEISVAC-C (Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)) medication page for patients to search for scientific information on Pfizer medications. Also, find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical Information.
NeisVac-C Baxter zapewnia wyłącznie ochronę przed zakażeniami Neisseria meningitidis grupy C, ale może niecałkowicie zapobiegać chorobom wywołanym przez meningokoki grupy C. Szczepienie nie chroni przed zakażeniami Neisseria meningitidis innych grup ani innymi drobnoustrojami powodującymi zapalenie opon mózgowych lub posocznicę. W
NeisVac-C er bóluefni sem notað er til bólusetningar við Neisseria meningitidis.Bóluefnið inniheldur hreinsað brot úr bakteríunni og vekur upp mótefnasvörun í líkamanum og kemur þannig í veg fyrir að fólk veikist af henni.
NeisVac-C | Lyf | Lyfja - Lifum heil
NeisVac-C® (meningococcal group C-TT conjugate vaccine, adsorbed) Product Monograph Page 5 of 23 It would be anticipated that functionally or anatomically asplenic individuals would mount an immune response to meningococcal C conjugate vaccines; however, there are NEISVAC-C (Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)) medication page for patients to search for scientific information on Pfizer medications. Also, find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical Information. NeisVac-C Baxter zapewnia wyłącznie ochronę przed zakażeniami Neisseria meningitidis grupy C, ale może niecałkowicie zapobiegać chorobom wywołanym przez meningokoki grupy C. Szczepienie nie chroni przed zakażeniami Neisseria meningitidis innych grup ani innymi drobnoustrojami powodującymi zapalenie opon mózgowych lub posocznicę. W NeisVac-C er bóluefni sem notað er til bólusetningar við Neisseria meningitidis.Bóluefnið inniheldur hreinsað brot úr bakteríunni og vekur upp mótefnasvörun í líkamanum og kemur þannig í veg fyrir að fólk veikist af henni.
NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life.
NeisVac-C: This medication belongs to the family of medications known as vaccines. It is used to prevent infections such as meningitis and blood infections caused by meningococcal group C bacteria (also called N. meningitidis serogroup C).
NeisVac-C is given to children from 8 weeks of age, adolescents, and adults. Action: How NeisVac-C works. Neisseria meningitidis can cause severe systemic infections, including meningitis and septicemia. Vaccination with meningococcal polysaccharides induces the production of bactericidal antibodies that are serogroup specific.
NeisVac-C ist indiziert zur aktivenImmunisierung von Kindern ab dem vollendeten Lebensmonat, Jugendlichen und Erwachsenen zur Prävention einer invasiven, durch Neisseria meningitidisder Serogruppe C verursachten Erkrankung. Hinsichtlich der Anwendung von NeisVac-C wird auf die aktuelle österreichische Impfempfehlung verwiesen.
FACHINFORMATION (Zusammenfassung der Merkmale des Arzneimittels)
NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. NeisVac-C: This medication belongs to the family of medications known as vaccines. It is used to prevent infections such as meningitis and blood infections caused by meningococcal group C bacteria (also called N. meningitidis serogroup C).
NeisVac-C is given to children from 8 weeks of age, adolescents, and adults. Action: How NeisVac-C works. Neisseria meningitidis can cause severe systemic infections, including meningitis and septicemia. Vaccination with meningococcal polysaccharides induces the production of bactericidal antibodies that are serogroup specific. NeisVac-C ist indiziert zur aktivenImmunisierung von Kindern ab dem vollendeten Lebensmonat, Jugendlichen und Erwachsenen zur Prävention einer invasiven, durch Neisseria meningitidisder Serogruppe C verursachten Erkrankung.
Hinsichtlich der Anwendung von NeisVac-C wird auf die aktuelle österreichische Impfempfehlung verwiesen.
NeisVac-C Vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. How to use this medicine . This medicine contains one component only.
For Product Information and Consumer Medicine Information about NeisVac-C visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
• NEISVAC-C® is the recommended and supplied product for the primary infant series. Any meningococcal C conjugate vaccine may be used for doses given at 18 months of age or older. • There must be an interval of at least 6 months between the administration of a
NeisVac-C kann auch gleichzeitigmit einem Schluckimpfstoff, der vor Rotavirus-Infektionen schützt, verabreicht werden. Schwangerschaft,Stillzeitund Fortpflanzungsfähigkeit Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger zu sein oder beabsichtigen,
Gebrauchsinformation:Information für Anwender - Pfizer
NeisVac-C Vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. How to use this medicine . This medicine contains one component only. For Product Information and Consumer Medicine Information about NeisVac-C visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
• NEISVAC-C® is the recommended and supplied product for the primary infant series. Any meningococcal C conjugate vaccine may be used for doses given at 18 months of age or older. • There must be an interval of at least 6 months between the administration of a NeisVac-C kann auch gleichzeitigmit einem Schluckimpfstoff, der vor Rotavirus-Infektionen schützt, verabreicht werden. Schwangerschaft,Stillzeitund Fortpflanzungsfähigkeit Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger zu sein oder beabsichtigen,
NEISVAC-C (meningococcal group C-TT conjugate vaccine, adsorbed) Product Information. Product Monograph (download PDF, 287KB) Patient Information (download PDF, 201KB) Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables.
For Product Information and Consumer Medicine Information about NeisVac-C visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life.
Prevention of meningococcal serogroup C disease by NeisVac-C
NEISVAC-C (meningococcal group C-TT conjugate vaccine, adsorbed) Product Information. Product Monograph (download PDF, 287KB) Patient Information (download PDF, 201KB) Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables.
For Product Information and Consumer Medicine Information about NeisVac-C visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s. NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life.
MenC vaccines licensed in the UK included NeisVac-C and Menjugate. Who should get the vaccine The schedule for MenC vaccination in the UK changed several times between 1999 and 2017, due to changing patterns of disease circulating:
NeisVac-C Suspension zur Injektion in einer Fertigspritze Stand: April 2024 Es wurde auch über die folgenden Nebenwirkungen berichtet: - Niedrige Blutplättchenzahl, mit der Folge von Bluter-güssen auf Haut und Schleimhäuten - Fieberkrämpfe - Hirnhautreizung - Verlust der Muskelspannung oder Schlappheit bei
A Meningococcusnak többféle szerotípusa ismert, ezek közül hazánkban a leggyakrabban a B- és a C-típus okoz megbetegedést. A C-típus ellen már régóta létezik védőoltás (Neisvac- C, Menjugate), ugyanígy a ritkábban előforduló A-, C-, W-, Y- szerotípusok ellen is (Nimenrix, Menveo).A B-típus elleni oltás (Bexsero) 2014 óta érhető el hazánkban.
NeisVac-C is a vaccine, a type of medicine used to help protect against infectious diseases Neis Vac-C is used to prevent invasive disease caused by bacteria called Neisseria meningitidis group C.
NeisVac-C Drug / Medicine Information - News-Medical.net
MenC vaccines licensed in the UK included NeisVac-C and Menjugate. Who should get the vaccine The schedule for MenC vaccination in the UK changed several times between 1999 and 2017, due to changing patterns of disease circulating: NeisVac-C Suspension zur Injektion in einer Fertigspritze Stand: April 2024 Es wurde auch über die folgenden Nebenwirkungen berichtet: - Niedrige Blutplättchenzahl, mit der Folge von Bluter-güssen auf Haut und Schleimhäuten - Fieberkrämpfe - Hirnhautreizung - Verlust der Muskelspannung oder Schlappheit bei A Meningococcusnak többféle szerotípusa ismert, ezek közül hazánkban a leggyakrabban a B- és a C-típus okoz megbetegedést. A C-típus ellen már régóta létezik védőoltás (Neisvac- C, Menjugate), ugyanígy a ritkábban előforduló A-, C-, W-, Y- szerotípusok ellen is (Nimenrix, Menveo).A B-típus elleni oltás (Bexsero) 2014 óta érhető el hazánkban. NeisVac-C is a vaccine, a type of medicine used to help protect against infectious diseases Neis Vac-C is used to prevent invasive disease caused by bacteria called Neisseria meningitidis group C.
